Temasek’s ClavystBio, Lightstone Ventures back Allay Therapeutics’ $57.5M Series D financing
Allay Therapeutics, a clinical-stage biotechnology company, announced last Thursday the completion of a $57.5 million Series D financing round with leading global investors. The firm said in a statement that Lightstone Ventures and Temasek-backed ClavystBio co-led the Series D financing with participation by existing investors NEA, Arboretum Ventures, Vertex Growth, Vertex Ventures Healthcare,...
0 التعليقات 0 المشاركات 434 مشاهدة 0 معاينة
إعلان مُمول
إعلان مُمول
Ifvex https://ifvex.com